Clinical Trials

4 enrolled

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

250 enrolled

Prostatic Neoplasms

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

120 enrolled 28 charts

Prostatic Neoplasms, Castration-Resistant

NCT03300505 2025-05-13

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

9 enrolled 14 charts

Prostatic Neoplasms

NCT02339168 2025-05-01

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT04094519 2024-11-20

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

24 enrolled

Prostatic Neoplasms

NCT03776968 2024-10-23

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

47 enrolled

Metastatic Castration Resistant Prostate Cancer

NCT03207529 2024-10-10

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06332170 2024-07-18

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Phase 1 Recruiting

610 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

49 enrolled 33 charts

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04033328 2023-12-15

Study of ORIC-101 in Combination With Enzalutamide

41 enrolled

Prostatic Neoplasms

NCT03751436 2023-10-16

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

10 enrolled

Prostatic Neoplasms

NCT03569280 2023-07-18

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

16 enrolled

Prostatic Neoplasms

NCT04179396 2023-06-29

RAMP

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT02740985 2023-05-26

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

GastrointestinalGenitourinaryThoracic

313 enrolled

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

12 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT02833883 2023-01-19

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

27 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

122 enrolled

Tumor-Agnostic

Neoplasms

NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

24 enrolled

Castration-resistant Prostate Cancer

NCT02138383 2021-08-17

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

25 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

6 enrolled

Prostate Adenocarcinoma

NCT03478904 2021-05-10

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

1 enrolled 8 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02125084 2021-05-04

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

38 enrolled

Prostatic Neoplasms

NCT02642913 2021-03-05

Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

28 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03774056 2020-11-03

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

43 enrolled

Metastatic Castration Resistant Prostate Cancer

NCT03778047 2020-11-03

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

10 enrolled

Metastatic Castration Resistant Prostate Cancer

NCT02215096 2020-10-22

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

37 enrolled 26 charts

Tumor-Agnostic

Neoplasms

NCT02500901 2019-10-21

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

2 enrolled 8 charts

Prostatic Neoplasms

NCT00510718 2019-10-03

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

140 enrolled 30 charts

Neoplasms, Prostatic Neoplasms

NCT02300610 2019-08-01

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

10 enrolled 14 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Ureteral Diseases, Ureteral Neoplasms, Urethral Neoplasms

NCT01597193 2019-05-08

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer